Boundless Bio to Present at the Guggenheim Oncology Conference

On February 2, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, reported that its Chief Executive Officer, Zachary Hornby, will present at the Guggenheim Oncology Conference, which will take place virtually (Press release, Boundless Bio, FEB 2, 2022, View Source [SID1234607640]). Presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Friday, February 11, 2022
Time: 2:00 PM – 2:25 PM EST

City of Hope Completes Strategic Acquisition of Cancer Treatment Centers of America, Building a National, Integrated Cancer Research and Treatment System With a Singular Focus on Eradicating Cancer

On February 2, 2022 City of Hope, a world-renowned, National Cancer Institute-designated comprehensive cancer center, reported that it has completed its acquisition of Cancer Treatment Centers of America (CTCA), a network of oncology hospitals and outpatient care centers across the United States, expanding access to world-class research and cancer care to patients nationally (Press release, City of Hope, FEB 2, 2022, View Source [SID1234607639]). City of Hope now has one of the largest geographic footprints in cancer research and treatment, providing cancer patients with timely access to exceptional care, clinical trials and leading-edge innovation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With the completion of this acquisition, City of Hope and Cancer Treatment Centers of America are combining complementary strengths, with a shared commitment to providing the best, most compassionate care possible," said Robert Stone, president and CEO of City of Hope and the Helen and Morgan Chu Chief Executive Officer Distinguished Chair. "Together, we are creating a new model for how cancer care is delivered, leveraging real-world cancer care experience to inform scientific innovation and making tomorrow’s new discoveries available to the people who need them today."

With CTCA, the combined organization will serve approximately 115,000 patients each year, with more than 11,000 team members and 575 physicians across a network of locations in California, Arizona, Illinois and Georgia, expanding the portfolio, reach and impact of City of Hope’s world-class cancer services and capabilities, including research and development, to more patients, families and communities nationwide.

J.P. Morgan acted as exclusive financial advisor and Jones Day acted as legal counsel to City of Hope in the transaction. Goldman Sachs & Co. acted as exclusive financial advisor and McDermott Will & Emery and Katten Muchin Rosenman LLP acted as legal counsel to CTCA.

With the completion of this acquisition, City of Hope intends to begin the process of converting CTCA to a nonprofit organization. CTCA President and CEO Pat Basu, M.D., will report directly to Stone.

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

On February 2, 2022 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that President and CEO Athena Countouriotis, M.D., will participate in the Guggenheim Healthcare Talks 2022 Oncology Day on February 9 and the 11th Annual SVB Leerink Global Healthcare Conference on February 16 (Press release, Turning Point Therapeutics, FEB 2, 2022, View Source [SID1234607638]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Countouriotis is scheduled to participate in fireside chats at 2 p.m. ET p.m. on February 9 and at noon ET on February 16. Both sessions will be accessible via webcast through the Investors page of www.tptherapeutics.com.

AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference

On February 2, 2022 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that Company management will participate in a fireside chat and one-on-one investor meetings during the SVB Leerink 11th Annual Global Healthcare Conference, taking place virtually February 14-18, 2022 (Press release, AC Immune, FEB 2, 2022, View Source [SID1234607637]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the fireside chat, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discuss the Company’s corporate strategy and upcoming milestones including seven clinical readouts planned this year for both therapeutic and diagnostic candidates in development in neurodegenerative diseases, while highlighting its precision medicine approach.

The fireside chat will take place on February 16, 2022, at 8:00 am ET / 2:00 pm CET. A webcast of the fireside chat will be available on the Events Page of AC Immune’s website. Following the fireside chat, a replay will be archived in the same location.

Fate Therapeutics to Present at Upcoming February Investor Conferences

On February 2, 2022 Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, reported that the Company will present at the following upcoming investor conferences (Press release, Fate Therapeutics, FEB 2, 2022, View Source [SID1234607636]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

4th Annual Guggenheim Oncology Day available on demand on Wednesday, February 9, 2022 at 11:00 AM ET
SVB Leerink 2022 Global Healthcare Conference on demand on Wednesday, February 16, 2022 at 3:00 PM ET
A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.